Icaritin alleviates docetaxel ‐induced skin injury by suppressing reactive oxygen species via estrogen receptors
ConclusionICT alleviates DTX-induced skin injury by suppressing ROS, reducing microtubule bundles, and blocking autophagy via ERs. Our study indicated that ICT may be a potential candidate for DTX-induced skin injury. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 26, 2021 Category: Cancer & Oncology Authors: Jie Zou, Meng ‐Xia Xu, Fang Li, Yu‐Hao Wang, Xiao‐Qian Li, Dao‐Jiang Yu, Yi‐Jia Ma, Yuan‐Yuan Zhang, Xiao‐Dong Sun Tags: ORIGINAL ARTICLE Source Type: research

Circulating cytokines associated with clinical outcomes in advanced non ‐small cell lung cancer patients who received chemoimmunotherapy
ConclusionsIn patients with advanced NSCLC who received chemoimmunotherapy, on-treatment increased IL-1 β and IFN-γ may serve as positive indicator of efficacy, while on-treatment increased IL-6 might play a predictive role of worse clinical outcome. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 26, 2021 Category: Cancer & Oncology Authors: Yuequan Shi, Xiaoyan Liu, Juan Du, Dongming Zhang, Jia Liu, Minjiang Chen, Jing Zhao, Wei Zhong, Yan Xu, Mengzhao Wang Tags: ORIGINAL ARTICLE Source Type: research

Onset of pulmonary Epstein –Barr virus‐positive diffuse large B‐cell lymphoma in a patient with silicosis
The underlying silicosis lesions showed predominant Th cells and M1/M2 macrophages, with a lack of B cells, Treg cells, and TRM cells. The imbalance of the immune cells in the microenvironment, at least in part, may help to explain how chronic inflammation contributes to EBV-positive diffuse large B-cell lymphoma. AbstractHow Epstein –Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) occasionally occurs following chronic inflammation remains to be elucidated. The case of a 57-year-old man who developed pulmonary EBV-positive DLBCL from underlying silicosis lesions is presented. Immunohistochemical exami...
Source: Thoracic Cancer - November 25, 2021 Category: Cancer & Oncology Authors: Ryosuke Ogata, Hiroshi Soda, Yasuhiro Tanaka, Hiroaki Senju, Midori Shimada, Koki Yamashita, Shota Nakashima, Asuka Umemura, Masataka Yoshida, Takuya Hara, Saeko Jinnai, Keisuke Iwasaki, Yuichi Fukuda, Hiroyuki Yamaguchi, Hiroshi Mukae Tags: CASE REPORT Source Type: research

LncRNA LINC00460: Function and mechanism in human cancer
In recent years, the regulatory role of long noncoding RNAs (lncRNAs) in human tumors has been gradually recognized. In this review, we respectively showed how lncRNA LINC00460 affected progression of human tumors in different types by multiple mechanisms. A large number of previous researches have demonstrated that LINC00460 as an oncogene plays important roles in tumor growth, development, and metastasis. In view of the important role of LINC00460 in tumorigenesis and development as well as its significance as a biomarker, we summarized the specific role and molecular mechanism of LINC00460 in various tumors, convenient ...
Source: Thoracic Cancer - November 25, 2021 Category: Cancer & Oncology Authors: Xi Chen, Jiwu Song, Xiaoxiao Wang, Dongyuan Sun, Yunxia Liu, Yingying Jiang Tags: REVIEW Source Type: research

Utility of mass spectrometry and artificial intelligence for differentiating primary lung adenocarcinoma and colorectal metastatic pulmonary tumor
ConclusionsMS combined with an AI system demonstrated high accuracy not only for differentiating cancer from normal tissue, but also for differentiating between PLAC and CRMPT with a short working time. This method shows potential for application as a support tool facilitating rapid intraoperative diagnosis to determine the surgical procedure for pulmonary resection. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 23, 2021 Category: Cancer & Oncology Authors: Wataru Shigeeda, Ryuichi Yosihimura, Yuji Fujita, Hidekazu Saiki, Hiroyuki Deguchi, Makoto Tomoyasu, Satoshi Kudo, Yuka Kaneko, Hironaga Kanno, Yoshihiro Inoue, Hajime Saito Tags: ORIGINAL ARTICLE Source Type: research

Solid histological component of adenocarcinoma might play an important role in PD ‐L1 expression of lung adenocarcinoma
In this study we aimed to clarify the PD-L1 positive expression in lung adenocarcinoma, including various adenocarcinoma subtypes paying particular attention to its component.MethodsA total of 307 lung adenocarcinoma patients who underwent lobectomy or segmentectomy, as well as systematic lymph node dissection (ND2a), from February 2008 to March 2020 at our hospital, were enrolled into the study. A final diagnosis of adenocarcinoma was obtained from the resected lung specimens of all 307 patients to determine the histological type, adenocarcinoma subtype, and component of adenocarcinoma by ethics of 5%. PD-L1 was immunohis...
Source: Thoracic Cancer - November 23, 2021 Category: Cancer & Oncology Authors: Tomoyuki Miyazawa, Kei Morikawa, Kanji Otsubo, Hiroki Sakai, Hiroyuki Kimura, Motohiro Chosokabe, Naoki Furuya, Hideki Marushima, Koji Kojima, Masamichi Mineshita, Junki Koike, Hisashi Saji Tags: ORIGINAL ARTICLE Source Type: research

Robot ‐assisted thoracic surgery versus video‐assisted thoracic surgery for treatment of patients with thymoma: A systematic review and meta‐analysis
ConclusionsRATS has more advantages over VATS, indicating that RATS is better than VATS in terms of postoperative recovery. We look forward to more large-sample, high-quality randomized controlled studies published in the future. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 23, 2021 Category: Cancer & Oncology Authors: Cheng Shen, Jialong Li, Jue Li, Guowei Che Tags: ORIGINAL ARTICLE Source Type: research

Construction of a circular RNA –microRNA–messenger RNA regulatory network of hsa_circ_0043256 in lung cancer by integrated analysis
ConclusionOur study constructed a circRNA –miRNA–mRNA network of hsa_circ_0043256. hsa_circ_0043256 may be a potential therapeutic target for lung cancer. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 22, 2021 Category: Cancer & Oncology Authors: Yongwen Li, Ruifeng Shi, Guangsheng Zhu, Chen Chen, Hua Huang, Min Gao, Songlin Xu, Peijun Cao, Zihe Zhang, Di Wu, Xuanguang Li, Hongyu Liu, Jun Chen Tags: ORIGINAL ARTICLE Source Type: research

Trend of lung cancer surgery, hospital selection, and survival between 2005 and 2016 in South Korea
ConclusionsThe trend of lung cancer surgery is changing. The current medical system is effective in providing lobectomy for patients including women, aged ≥76 years, city residents, and middle-income. Increasing tendency to choose an HOR requires further study. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 20, 2021 Category: Cancer & Oncology Authors: Dohun Kim, Gil ‐Won Kang, Hoyeon Jang, Jun Yeun Cho, Bumhee Yang, Hee Chul Yang, Jinwook Hwang Tags: ORIGINAL ARTICLE Source Type: research

Response to clinical evaluation of the effectiveness of fusion ‐induced asymmetric transcription assay‐based reverse transcription droplet digital PCR for ALK detection in formalin‐fixed paraffin‐embedded samples from lung cancer
(Source: Thoracic Cancer)
Source: Thoracic Cancer - November 20, 2021 Category: Cancer & Oncology Authors: Cynthia Pe ñaloza Coronas, Silvia Mariela Montilla Fonseca, Mirna L. Sánchez Tags: LETTER TO THE EDITOR Source Type: research

Improved survival in patients with unresectable stage III EGFR ‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
ConclusionThis current study suggests that EGFR-TKIs is a better choice for patients with unresectable stage IIIEGFR-mutant adenocarcinoma. However, further randomized studies are required to validate the results. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 20, 2021 Category: Cancer & Oncology Authors: Sheng ‐Yuan Wang, Ching‐Han Lai, Chian‐Wei Chen, Szu‐Chun Yang, Chao‐Chun Chang, Chia‐Ying Lin, Yi‐Ting Yen, Yau‐Lin Tseng, Po‐Lan Su, Chien‐Chung Lin, Wu‐Chou Su Tags: ORIGINAL ARTICLE Source Type: research

Non ‐incisional pleurectomy/decortication for malignant mesothelioma after cardiac surgery
We successfully treated a patient with malignant epithelial pleural mesothelioma who underwent pleurectomy/decortication after cardiac surgery with median sternotomy. Pleurectomy/decortication is possible for the patients who underwent cardiac surgery with median sternotomy. AbstractA 70-year-old man diagnosed with right-sided malignant epithelial pleural mesothelioma, underwent pleurectomy/decortication after three courses of neoadjuvant chemotherapy. He had a history of mitral valve replacement and maze procedure with median sternotomy, and the procedures resulted in strong adhesion from the apex to the mediastinal side....
Source: Thoracic Cancer - November 20, 2021 Category: Cancer & Oncology Authors: Kentaro Miura, Kimihiro Shimizu, Seiki Hasegawa, Sachie Koike, Shunichiro Matsuoka, Tetsu Takeda, Takashi Eguchi, Kazutoshi Hamanaka, Momoko Takizawa Tags: CASE REPORT Source Type: research

Circulating tumor DNA predicts the outcome of chemotherapy in patients with lung cancer
ConclusionsThe dynamic detection of plasma ctDNA VAF has the potential value as a biomarker for evaluating the efficacy of chemotherapy in patients with SCLC and advanced NSCLC, and may predict the progression of lung cancer patients earlier than radiography. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 18, 2021 Category: Cancer & Oncology Authors: Min Zhang, Chao Huang, Huan Zhou, Dan Liu, Runze Chen, Xiuhua Li, Ye Cheng, Bing Gao, Jun Chen Tags: ORIGINAL ARTICLE Source Type: research

Radiation recall pneumonitis after COVID ‐19 vaccination
(Source: Thoracic Cancer)
Source: Thoracic Cancer - November 18, 2021 Category: Cancer & Oncology Authors: Kanako Shinada, Shuji Murakami, Daisaku Yoshida, Haruhiro Saito Tags: CASE IMAGE Source Type: research

Impact of docetaxel plus ramucirumab in a second ‐line setting after chemoimmunotherapy in patients with non‐small‐cell lung cancer: A retrospective study
The objective response rate in patients treated with docetaxel plus ramucirumab was significantly higher than that in patients treated with a single-agent chemotherapy regimen (55.6% vs. 0%,p 
Source: Thoracic Cancer - November 18, 2021 Category: Cancer & Oncology Authors: Masaki Ishida, Kenji Morimoto, Tadaaki Yamada, Shinsuke Shiotsu, Yusuke Chihara, Takahiro Yamada, Osamu Hiranuma, Yoshie Morimoto, Masahiro Iwasaku, Shinsaku Tokuda, Takayuki Takeda, Koichi Takayama Tags: ORIGINAL ARTICLE Source Type: research

Best regimens for treating chemo ‐naïve incurable squamous non‐small cell lung cancer with a programmed death‐ligand 1 tumor proportion score of 1%–49%: A network meta‐analysis
ConclusionsThe combination therapies, which were the platinum regimen + Pemb and the platinum regimen + Niv  + Ipi, rather than ICI monotherapy were effective first-line agents for treating squamous NSCLC with low PD-L1 levels. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 18, 2021 Category: Cancer & Oncology Authors: Nobuhiko Fukuda, Nobuyuki Horita, Ho Namkoong, Ayami Kaneko, Kohei Somekawa, Yoichi Tagami, Keisuke Watanabe, Yu Hara, Nobuaki Kobayashi, Takeshi Kaneko Tags: ORIGINAL ARTICLE Source Type: research

Efficacy and safety of 3 mg pegylated recombinant human granulocyte colony ‐stimulating factor as support to chemotherapy for lung cancer
PEG rhG-CSF (3  mg) decreased the incidence of acute lower respiratory tract infection. PEG rhG-CSF (3 mg) could prevent neutropenia and FN. Preventive application of PEG rhG-CSF contributed to the reduction of the associated medical expenditures. AbstractBackgroundNCCN guidelines recommend a dose of 100  μg/kg or a fixed dose of 6 mg pegylated recombinant human granulocyte colony-stimulating factor (PEG rhG-CSF) for chemotherapy-induced neutropenia. However, a single dose of 60 μg/kg or 100 μg/kg produced a similar neutrophil response among patients with chemotherapy-induced ne...
Source: Thoracic Cancer - November 18, 2021 Category: Cancer & Oncology Authors: Xiang Ji, Lisheng Xu, Pengfei Pan, Zhiyun Xu, Aihua Wang, Yu Li Tags: ORIGINAL ARTICLE Source Type: research

Issue Information
(Source: Thoracic Cancer)
Source: Thoracic Cancer - November 14, 2021 Category: Cancer & Oncology Tags: ISSUE INFORMATION Source Type: research

LncRNA and mRNA expression associated with myasthenia gravis in patients with thymoma
ConclusionMG-positive thymoma is associated with overactive biological processes and molecular functions, especially dephosphorylation and hydrolysis, which may affect thymocyte survival during selection in the thymus. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 14, 2021 Category: Cancer & Oncology Authors: Ji Ke, Xin Du, Jian Cui, Lei Yu, Hui Li Tags: ORIGINAL ARTICLE Source Type: research

Active cycle of breathing technique may reduce pulmonary complications after esophagectomy: A randomized clinical trial
The effect of the active cycle of breathing technique (ACBT) on postoperative pulmonary complication (PPC) after esophagectomy has not yet been investigated. In this randomized clinical trial that included 291 patients with resectable thoracic esophageal carcinoma, the PPC rate was significantly lower in the ACBT group (15.2%) than in the control group (31.0%) (p = 0.001) after esophagectomy. AbstractBackgroundThe purpose of the study was to determine whether the active cycle of breathing technique (ACBT) has an impact on postoperative pulmonary complication (PPC) after esophagectomy.MethodsIn this prospective ra...
Source: Thoracic Cancer - November 13, 2021 Category: Cancer & Oncology Authors: Jiudi Zhong, Siwen Zhang, Chuangzhen Li, Yi Hu, Weijin Wei, Li Liu, Ming Wang, Zhangxian Hong, Hao Long, Tiehua Rong, Hong Yang, Xiaodong Su Tags: ORIGINAL ARTICLE Source Type: research

Sarcoidosis ‐like reaction after neoadjuvant pembrolizumab combined with chemotherapy mimicking disease progression of NSCLC induced encouraging discovery of pathological complete response
We report a stage IIIa patient with non-small cell lung cancer who underwent neoajuvant chemoimmunotherapy. The CT scan were captured before treatment, after 2 cycles of treatment and before surgery. AbstractNeoadjuvant chemoimmunotherapy has demonstrated improved efficacy and prognosis in stage IIa –IIIb patients with non-small cell lung cancer (NSCLC). Drug-induced sarcoidosis-like reaction (DISR), an autoimmune reaction, has been reported as a type of immune-related adverse event that may mimic disease progression. Here, we report the case of patient with NSCLC who developed DISR during ne oadjuvant chemoimmunothe...
Source: Thoracic Cancer - November 12, 2021 Category: Cancer & Oncology Authors: Yuequan Shi, Ji Li, Minjiang Chen, Hongsheng Liu, Dongjie Ma, Yuxiao Lin, Mengzhao Wang, Yan Xu Tags: CASE REPORT Source Type: research

Efficacy of dacomitinib in patients with EGFR ‐mutated NSCLC and brain metastases
ConclusionThis study suggests that dacomitinib demonstrated CNS efficacy in patients with EGFR TKI-na ïve EGFR-mutated NSCLC in the real-world setting. The safety profile was tolerable and manageable. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 9, 2021 Category: Cancer & Oncology Authors: Jinyao Zhang, Yan Wang, Ziling Liu, Lin Wang, Yu Yao, Yutao Liu, Xue Zhi Hao, Jianyang Wang, Puyuan Xing, Junling Li Tags: ORIGINAL ARTICLE Source Type: research

Lung cancer risk following previous abnormal chest radiographs: A 27 ‐year follow‐up study of a Chinese lung screening cohort
ConclusionsThe increased risk was significant for both squamous cell carcinoma and adenocarcinoma. Although decreased over time, an increased lung cancer risk relative to abnormal CXR findings can continue for 10  years. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 9, 2021 Category: Cancer & Oncology Authors: Yaguang Fan, Zheng Su, Mengna Wei, Hao Liang, Yong Jiang, Xuebing Li, Zhaowei Meng, Ying Wang, Heng Wu, Jinzhao Song, Youlin Qiao, Qinghua Zhou Tags: ORIGINAL ARTICLE Source Type: research

Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer
ConclusionSpecific circulating miRNAs were identified as predictive markers for NAC response and prognosis in luminal B BC. The underlying mechanism needs further studies. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 9, 2021 Category: Cancer & Oncology Authors: Zhuo Zhang, Hanxu Zhang, Chao Li, Qian Xiang, Ling Xu, Qianxin Liu, Xiaocong Pang, Wenjia Zhang, Hong Zhang, Shuang Zhang, Xuening Duan, Yinhua Liu, Yimin Cui Tags: ORIGINAL ARTICLE Source Type: research

Diagnostic performance of SHOX2 promoter methylation as biomarker for lung cancer identification: A meta ‐analysis update
ConclusionSHOX2 promoter methylation in humoral components may be a potential biomarker for lung cancer diagnosis with relative high diagnostic specificity. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 6, 2021 Category: Cancer & Oncology Authors: Xiaoxi Zhou, Xiaoling Lu, Haiyan Wu, Juan Liu, He Huang Tags: ORIGINAL ARTICLE Source Type: research

Intrapleural treatment in patients with non ‐small cell lung cancer with malignant pleural effusions in the real world
ConclusionsIntrapleural treatment can prolong the survival of NSCLC patients with MPE who do not receive targeted treatment or who only receive chemotherapy. The PE-CEA: B-CEA ratio can be used to predict the efficacy if intrapleural treatment is indicated. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 6, 2021 Category: Cancer & Oncology Authors: Pengfei Pan, Fengjuan Wu, Zhiyun Xu, Xiang Ji, Qian Qi, Xiaomin Huang, Ruyue Zhao, Mingtao Liu, Peng Jiang, Yu Li, Lisheng Xu Tags: ORIGINAL ARTICLE Source Type: research

The reversal of drug resistance by two ‐dimensional titanium carbide Ti2C (2D Ti2C) in non‐small‐cell lung cancer via the depletion of intracellular antioxidant reserves
Conclusions2D Ti2C can reverse NSCLC chemoresistance both in vitro and in vivo, suggesting that it may potentially become a novel and effective means to treat chemoresistant NSCLC in the clinic. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 6, 2021 Category: Cancer & Oncology Authors: Yue Zhu, Baiyan Sui, Xin Liu, Jiao Sun Tags: ORIGINAL ARTICLE Source Type: research

Circular RNA circCPA4 promotes tumorigenesis by regulating miR ‐214‐3p/TGIF2 in lung cancer
ConclusionsCircCPA4 could act as a sponge of miR-214-3p to upregulate TGIF2 expression, thereby promoting the progression of lung cancer cells. These findings suggested underlying therapeutic targets for the treatment of lung cancer. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 6, 2021 Category: Cancer & Oncology Authors: Wenhu Tao, Cheng Cao, Gaofei Ren, Decun Zhou Tags: ORIGINAL ARTICLE Source Type: research

Formation, contents, functions of exosomes and their potential in lung cancer diagnostics and therapeutics
Formation and secretion of exosomes by donor cells and uptake of exosomal contents by recipient cells. Diverse applications of tumor-derived exosomes in lung cancer management. AbstractLung cancer is the leading cause of cancer-related death worldwide due to diagnosis in the advanced stage and drug resistance in the subsequent treatments. Development of novel diagnostic and therapeutic methods is urged to improve the disease outcome. Exosomes are nano-sized vehicles which transport different types of biomolecules intercellularly, including DNA, RNA and proteins, and are implicated in cross-talk between cells and their surr...
Source: Thoracic Cancer - November 4, 2021 Category: Cancer & Oncology Authors: Zhenkun Xia, Bei Qing, Wei Wang, Linguo Gu, Hongzuo Chen, Yunchang Yuan Tags: REVIEW Source Type: research

Prognostic factors of T2aN0M0 (T3 ‐4cmN0M0, stage IB) non‐small‐cell lung cancer after surgery: Single‐center real‐world research
ConclusionsWe found that N2-LSNDr were independent influencing factors affecting the prognosis in all included stage IB patients and stage IB patients without adjuvant chemotherapy. ASC was associated with worse prognosis of T2aN0M0 NSCLC. Older age is an independent prognostic factor of the worst OS in stage IB patients without adjuvant chemotherapy. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 4, 2021 Category: Cancer & Oncology Authors: Lei Liu, Jiaqi Zhang, Guige Wang, Ke Zhao, Chao Guo, Yeye Chen, Cheng Huang, Shanqing Li Tags: ORIGINAL ARTICLE Source Type: research

Hexokinases II ‐mediated glycolysis governs susceptibility to crizotinib in ALK‐positive non‐small cell lung cancer
ConclusionsThese results indicate that HK2-mediated glycolysis plays a crucial role in the increased tolerance of ALK+ NSCLC cells to crizotinib. 2DG may sensitize ALK+ NSCLC to crizotinib via suppression of HK2-mediated glycolysis and the AKT/mTOR signaling pathway. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 3, 2021 Category: Cancer & Oncology Authors: Caiyu Lin, Hengyi Chen, Rui Han, Li Li, Conghua Lu, Shuai Hao, Yubo Wang, Yong He Tags: ORIGINAL ARTICLE Source Type: research

The promoter hypermethylation of SULT2B1 accelerates esophagus tumorigenesis via downregulated PER1
ConclusionsSULT2B1 loss is a consequence owing to its ability to promote hypermethylation. In addition, it serves as a suppressor and poor-prognosis factor because of the post-transcriptional regulation of PER1 in ESCC. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 3, 2021 Category: Cancer & Oncology Authors: Zhuo Li, Meng ‐Yan Li, Ling‐Ling Wang, Lei Li, Qing‐Yun Chen, Ying‐Hui Zhu, Yan Li, Yan‐ru Qin, Xin‐Yuan Guan Tags: ORIGINAL ARTICLE Source Type: research

Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report
The patient received afatinib for recurrent lung cancer (a) with a partial response (b). The patient had progressed disease (c) and rebiopsy of lung tumor showed positiveEGFR exon 20 p.T790M mutation. He had a partial response to osimertinib treatment (d) AbstractTyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR) are the standard treatment for lung cancer patients with activatingEGFR mutation. The traditional direct polymerase chain reaction (PCR) has lower sensitivity in the detection ofEGFR mutations in patient tissue samples. Whilst PCR amplification kits increase the sensitivity in detecting s...
Source: Thoracic Cancer - November 3, 2021 Category: Cancer & Oncology Authors: Yueh ‐Fu Fang, Ping‐Chi Liu Tags: CASE REPORT Source Type: research

Corrigendum
(Source: Thoracic Cancer)
Source: Thoracic Cancer - November 2, 2021 Category: Cancer & Oncology Tags: CORRIGENDUM Source Type: research

Issue Information
(Source: Thoracic Cancer)
Source: Thoracic Cancer - November 2, 2021 Category: Cancer & Oncology Tags: ISSUE INFORMATION Source Type: research

CT ‐guided microwave ablation in patients with lung metastases from breast cancer
ConclusionCT-guided percutaneous MWA may be safe and effective for treating lung metastases from breast cancer. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 2, 2021 Category: Cancer & Oncology Authors: Min Meng, Xiaoying Han, Wenhong Li, Guanghui Huang, Yang Ni, Jiao Wang, Tiehong Zhang, Jianjian Dai, Zhigeng Zou, Xia Yang, Xin Ye Tags: ORIGINAL ARTICLE Source Type: research

Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small ‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy
The current study aimed to evaluate the serum pretreatment lactate dehydrogenase (LDH) and overall survival (OS) in small-cell lung cancer (SCLC) patients who received first-line platinum-containing chemotherapy. A total of 234 SCLC patients, who received first-line platinum-based chemotherapy between 2013 and 2018, were retrospectively analyzed. Age
Source: Thoracic Cancer - November 2, 2021 Category: Cancer & Oncology Authors: Man He, Xiaorui Chi, Xinyan Shi, Yang Sun, Xue Yang, Leirong Wang, Bingrui Wang, Hongmei Li Tags: ORIGINAL ARTICLE Source Type: research

Effects of mediastinal lymph node dissection in colorectal cancer ‐related pulmonary metastasectomy
This study aimed to determine whether MLND affects survival in patients undergoing PM and to identify the prognostic factors for survival.MethodsWe retrospectively reviewed 275 patients who had undergone colorectal cancer-related PM from January 2010 to December 2016. MLND was defined as the resection of at least six mediastinal lymph node stations according to the International Association for the Study of Lung Cancer criteria (N1, ≥3 stations; N2, ≥3 stations). The propensity score matching method was used to reduce bias.ResultsThirty-three (12%) patients underwent MLND, and 13 (4.7%) patients had mediastinal lymph...
Source: Thoracic Cancer - October 31, 2021 Category: Cancer & Oncology Authors: Young Ho Yang, Seong Yong Park, Ha Eun Kim, Byung Jo Park, Chang Young Lee, Jin Gu Lee, Dae Joon Kim, Hyo Chae Paik Tags: ORIGINAL ARTICLE Source Type: research

Predictive value of a novel Asian lung cancer screening nomogram based on artificial intelligence and epidemiological characteristics
ConclusionsOur study showed that epidemiological characteristics should be considered in lung cancer screening, which can significantly improve the efficiency of the artificial intelligence (AI) model alone. We combined the CNN model score with Asian lung cancer epidemiological characteristics to develop a new nomogram to facilitate and accurately perform individualized lung cancer screening, especially for Asians. (Source: Thoracic Cancer)
Source: Thoracic Cancer - October 29, 2021 Category: Cancer & Oncology Authors: Dahai Liu, Xiao Sun, Ao Liu, Lun Li, Shaoke Li, Jinmiao Li, Xiaojun Liu, Yu Yang, Zhe Wu, Xiaoliang Leng, Yang Wo, Zhangfeng Huang, Wenhao Su, Wenxing Du, Tianxiang Yuan, Wenjie Jiao Tags: ORIGINAL ARTICLE Source Type: research

Prediction modeling using routine clinical parameters to stratify survival in malignant pleural mesothelioma patients complicated with malignant pleural effusion
ConclusionsUsing routinely available clinical variables, both LENT and BRIMS scores could stratify selected MPM and MPE patients into risk groups with statistically different survival. (Source: Thoracic Cancer)
Source: Thoracic Cancer - October 28, 2021 Category: Cancer & Oncology Authors: Shu Zhang, Yuan Zhang, Wei Feng, Zhongyue Shi, Huanzhong Shi, Yuhui Zhang Tags: ORIGINAL ARTICLE Source Type: research

Response and safety of whole ‐brain radiotherapy plus temozolomide for patients with brain metastases of non‐small‐cell lung cancer: A meta‐analysis
Twenty-five studies reported the treatment response and the pooled results showed whole-brain radiotherapy (WBRT) plus temozolomide can significantly improve the objective response rate compared WBRT alone (relative risk  = 1.43, 95% confidence interval 1.32–1.55,p 
Source: Thoracic Cancer - October 27, 2021 Category: Cancer & Oncology Authors: Jianguo Han, Ming Qiu, Li Su, Chong Wu, Si Cheng, Zhijun Zhao, Danxia Li, Menghui Wang, Wei Tao, Shiwei Du Tags: ORIGINAL ARTICLE Source Type: research

Comparing survival and treatment response of patients with acquired T790M mutation second ‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study
ConclusionThis real-world analysis revealed that previous chemotherapy could affect the treatment outcomes of patients with non-small cell lung cancer treated with osimertinib. Osimertinib treatment following first/second generation EGFR-TKI treatment or chemotherapy resulted in improved survival benefit. (Source: Thoracic Cancer)
Source: Thoracic Cancer - October 27, 2021 Category: Cancer & Oncology Authors: Chin ‐Chou Wang, Chien‐Hao Lai, Yu‐Ping Chang, Huang‐Chih Chang, Chia‐Cheng Tseng, Kuo‐Tung Huang, Meng‐Chih Lin Tags: ORIGINAL ARTICLE Source Type: research

Diagnostic utility of transbronchial biopsy for Hodgkin's lymphoma: A case study
Here, we report a case of undiagnosed HL with lung lesions despite multiple TBBs. Our literature review indicated that the diagnostic success rate of TBB was low (18.5%) in cases of lung lesions in HL. Surgical biopsy should be considered early to avoid a delay in diagnosis because the diagnostic ability of TBB for HL patients with lung lesions is limited. AbstractLung lesions of Hodgkin's lymphoma (HL) are rare and difficult to diagnose by nonsurgical biopsy. We herein present the case of a 72-year-old Japanese male who presented with accumulation of lung infiltrates and masses bilaterally on the lungs for 3  years...
Source: Thoracic Cancer - October 26, 2021 Category: Cancer & Oncology Authors: Miki Hoshi, Nobuaki Kobayashi, Katsushi Tanaka, Kohei Somekawa, Ayami Kaneko, Ami Izawa, Kenichi Seki, Yoichi Tagami, Ayako Aoki, Hiroaki Fujii, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Mai Matsumura, Makiko Enaka, Maki Hagihara, Takesh Tags: CASE REPORT Source Type: research

Capmatinib successfully overcomes tepotinib ‐induced intolerable peripheral edema
Peripheral edema has been identified as one of the most common adverse events in capmatinib and tepotinib; however, there is no unified management for this side effect. This is the first report that two MET inhibitors have different effects on the development of peripheral edema, and that the MET inhibitors can be continued by switching these drugs. AbstractIn May 2020 and February 2021, capmatinib and tepotinib, respectively were approved by the Food and Drug Administration (FDA) for the treatment of metastatic non-small cell lung carcinoma harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations. He...
Source: Thoracic Cancer - October 25, 2021 Category: Cancer & Oncology Authors: Kei Kunimasa, Takahisa Kawamura, Motohiro Tamiya, Takako Inoue, Hanako Kuhara, Kazumi Nishino, Toru Kumagai Tags: CASE REPORT Source Type: research

Heterogeneous radiological response to chemotherapy is associated with poor prognosis in advanced non ‐small‐cell lung cancer
ConclusionsThe presence of lesions with radiological heterogeneity was associated with disease progression and poor prognosis in the SD group. Patients with heterogeneous radiological responses require careful monitoring. (Source: Thoracic Cancer)
Source: Thoracic Cancer - October 25, 2021 Category: Cancer & Oncology Authors: Woo Kyung Ryu, Jung Soo Kim, Mi Hwa Park, Minkyung Lee, Hyun ‐Jung Kim, Jeong‐Seon Ryu, Jun Hyeok Lim Tags: ORIGINAL ARTICLE Source Type: research

A “water”‐based educational intervention to increase the public's utilization of low‐dose computed tomography‐based lung‐cancer screening services
(Source: Thoracic Cancer)
Source: Thoracic Cancer - October 25, 2021 Category: Cancer & Oncology Authors: Bernard M. H. Law, Winnie K. W. So, Cho Lee Wong Tags: EDITORIAL Source Type: research

Intestinal flora characteristics of advanced non ‐small cell lung cancer in China and their role in chemotherapy based on metagenomics: A prospective exploratory cohort study
ConclusionsThe intestinal flora of Chinese patients with advanced NSCLC differed according to sex and age. Moreover, significant differences in the intestinal flora were noted after chemotherapy, which could be associated with chemotherapy-induced gastrointestinal reactions and the efficacy of chemotherapy. (Source: Thoracic Cancer)
Source: Thoracic Cancer - October 25, 2021 Category: Cancer & Oncology Authors: Min Zhang, Dan Liu, Huan Zhou, Xiangjun Liu, Xiuhua Li, Ye Cheng, Bing Gao, Jun Chen Tags: ORIGINAL ARTICLE Source Type: research

Risk factors for surgical complications after anatomic lung resections in the era of VATS and ERAS
ConclusionThoracotomy was associated with a 10-fold increased risk for postoperative complications compared with minimally invasive surgery and was an independent risk factor for surgical complications. In the era of VATS and ERAS, the fact that thoracotomy is performed may be a reliable parameter to identify patients at risk for postoperative complications. (Source: Thoracic Cancer)
Source: Thoracic Cancer - October 25, 2021 Category: Cancer & Oncology Authors: Christian Galata, Ioannis Karampinis, Eric D. Roessner, Davor Stamenovic Tags: ORIGINAL ARTICLE Source Type: research

Impact of tumor size and location on lung dose difference between stereotactic body radiation therapy techniques for non ‐small cell lung cancer
ConclusionsLung dose differences between the 3D-CRT and IMRT techniques for lung SBRT were mainly correlated with the PTV rather than location-related parameters. Together with the dosimetric benefit in high-dose lung regions of IMRT for larger tumors, the relative increases in the MLD and V20 for small-sized tumors could be reduced by applying a more rapid dose fall-off outside the PTV. (Source: Thoracic Cancer)
Source: Thoracic Cancer - October 24, 2021 Category: Cancer & Oncology Authors: Seong Soon Jang, Yohan Shin, Suk Young Park, Gil Ja Huh, Young Jun Yang Tags: ORIGINAL ARTICLE Source Type: research

Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy
Late concurrent chemoradiation therapy following systemic therapy (immunotherapy or immunochemotherapy) should be considered as an important treatment option for patients initially judged ineligible for definitive chemoradiation therapy. AbstractConcurrent chemoradiation therapy (CRT) is the standard of care for patients with unresectable stage II/III lung cancer. However, systemic chemotherapy is required for patients who are ineligible for radical radiation therapy. There is little evidence to date for the safety and efficacy of CRT administered after treatment with immune checkpoint inhibitors (ICIs). The cases reported...
Source: Thoracic Cancer - October 24, 2021 Category: Cancer & Oncology Authors: Taichi Matsubara, Shinkichi Takamori, Takatoshi Fujishita, Ryo Toyozawa, Kensaku Ito, Masafumi Yamaguchi, Takashi Seto, Tatsuro Okamoto Tags: CASE REPORT Source Type: research